Stoke Therapeutics, Inc. · Brief

Next report

69 days

Jan 11 · before openest.Q4 FY26

Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory

1 of 8≥ implied

avg implied: ±13.7%
avg realized: ±7.8%

Mar 18 '25±7.6%▼−1.44%×0.19

May 13 '25±11.8%▼−7.56%×0.64

Aug 12 '25±13.8%▲+24.98%×1.81

Nov 4 '25±22.6%▼−9.94%×0.44

Jan 12 '26±18.0%▼−10.44%×0.58

Q1 FY26±14.5%▲+0.30%×0.02

Q2 FY26±10.8%▲+7.14%×0.66

Oct 29 '26±10.1%▼−0.23%×0.02

quarterimplied−25%0+25%realized×

Oct '26±10.1%▼−0.23%×0.02

Q2 FY26±10.8%▲+7.14%×0.66

Q1 FY26±14.5%▲+0.30%×0.02

Jan '26±18.0%▼−10.44%×0.58

Nov '25±22.6%▼−9.94%×0.44

Aug '25±13.8%▲+24.98%×1.81

2 older reports

May '25±11.8%▼−7.56%×0.64

Mar '25±7.6%▼−1.44%×0.19

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Jan 11 report · est.

Bull2 of 3

3disclosed supplier and customer tiesSEC filings

198managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

7 of 8recent reports where move came in under the options implied rangeEarnings history

0.48%of State Street SPDR S&P Biotech ETF assets the largest tracked fund weightN-PORT · Jun 30 '26

AI captions · Nov 2 '26once per report · top 2 per case

Linked exposure

STOK report session

Customers 1

ACADAcadia Pharmaceuticals×0.23

× = co-movement · max 501dSource: SEC filings · market data

Latest changes

30 daysAll changes

Oct 29impliedImplied move: ±10.1% into Oct 29 earnings (Oct 29 close).Source

Oct 20impliedImplied move: ±13.7% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.